एस्मोलोल और प्रोपाफेनोन का इंटरैक्शन

• The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk in patients with structural heart disease.

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval.

In clinical trials using propafenone immediate-release tablets, patients who were receiving beta-blockers concurrently did not experience an increased incidence of side effects.

Concurrent use of propafenone with other antiarrhythmic agents has not been well studied.